Clinical Trials Logo

Colorectal Neoplasm clinical trials

View clinical trials related to Colorectal Neoplasm.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05953662 Recruiting - Colorectal Neoplasm Clinical Trials

Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Colorectal cancer is the third most common malignant tumor. Radical resection is the mainstay of treatments for non-metastatic colorectal cancer. In case of traditional laparoscopic surgery, inexperienced assistants are likely to cause side injuries and interfere surgeon due to limited operating space. Reduced-port laparoscopic surgery has only 3 ports for surgeon and observer, and the surgeon completes the surgery independently, which increases the difficulty of the operation. However, reduced-port laparoscopy has some potential advantages and applications. Reduced-port laparoscopic surgery avoids the prolongation of the operation time and parainjury caused by inexperienced assistant. Reduced-port laparoscopy reduces some surgical incisions, resulting in less pain and faster recovery. Reduced-port laparoscopy also reduces the consumables, human resources and medical expenses. This study aims to evaluate the curative effect and safety of reduced-port laparoscopic surgery versus conventional laparoscopic surgery for resectable colorectal cancer.

NCT ID: NCT04866862 Recruiting - Colorectal Neoplasm Clinical Trials

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Start date: April 26, 2021
Phase: Phase 2
Study type: Interventional

Limited agents are optional after standard first and second line treatment for mCRC. Nowadays, cancer therapy has entered the era of immunotherapy. The approved cancer therapies include pembrolizumab and nivolumab, but only for MSI-H patients. 95% of non MSI-H / dMMR patients with advanced colorectal cancer can not benefit from them. Therefore, the use of PD-1 / PD-L1 monoclonal antibody in mCRC is greatly limited. Our previous research showed that anti-PD-1 combined with Fruquintinib can significantly inhibit the growth of CRC in MSS mice. At the same time, a retrospective clinical study showed that patients with MSS CRC can benefit from Sintilimab combined with Fruquintinib. Camrelizumab is PD-1 monoclonal antibody, which has been approved for a variety of tumors. The prospective clinical trial of Camrelizumab combined with Fruquintinib may bring new hope for the treatment of non MSI-H / dMMR patients with mCRC.This study is aimed to explore the efficacy, safety in advanced colorectal cancer failed to standard therapy in Chinese population.

NCT ID: NCT04856423 Recruiting - Colorectal Neoplasm Clinical Trials

Ultra-sensitivity Quantitative Fecal Immunochemical Test in Detecting Colorectal Advanced Adenoma and Colorectal Cancer

Start date: April 19, 2021
Phase:
Study type: Observational

Early detecting and removing of colorectal advanced adenomas can reduce the incidence of colorectal cancer. Because of the less bleeding of advanced adenomas, sensitivities of the common used quantitative fecal immunochemical tests (qFITs) are unsatisfying. Ultra-sensitivity qFIT(us-qFIT) can determine extremely low fecal hemoglobin concentration compared with the common used qFIT. This study will prove the diagnostic accuracy of us-qFIT in detecting colorectal advanced adenomas.

NCT ID: NCT04185779 Recruiting - Colorectal Cancer Clinical Trials

COLO-COHORT (Colorectal Cancer Cohort) Study

Start date: December 13, 2019
Phase:
Study type: Observational

This is a cross-sectional study aimed at identifying factors which best predicts patients at high risk of colorectal cancer or colorectal adenomas and to develop a risk prediction model.

NCT ID: NCT04160832 Recruiting - Colorectal Neoplasm Clinical Trials

Prevalence and Spectrum of Cancer Susceptibility Among Patients With Advanced Colorectal Polyps

Start date: October 24, 2019
Phase:
Study type: Observational

The study is being conducted to determine the prevalence and risk factors for germline cancer susceptibility genetic mutations among patients with advanced colorectal polyps.

NCT ID: NCT04008407 Recruiting - Colorectal Neoplasm Clinical Trials

ESD for Colorectal LSL Using a Selective Strategy - a Prospective Cohort Study

COVERT
Start date: August 14, 2017
Phase: N/A
Study type: Interventional

Colonic Laterally spreading lesions (LSL) => 20mm are at high risk to progress to cancer. Overt stigmata of submucosal invasive cancer (SMIC) has been well characterized and includes ulceration and surface pit pattern changes as per the Kudo classification of type V. In a recent report, risk factors for LSL with SMIC and no overt stigmata (i.e. covert SMIC) were described. Resection of these lesions 'en-bloc' can allow for better histological staging and potentially reduce the need for surgical resection.

NCT ID: NCT03451643 Recruiting - Colorectal Neoplasm Clinical Trials

Stenting and Resection for Stage IV Colorectal Cancer Endoscopic Stenting and Colorectal Resection in Stage IV

Start date: February 2013
Phase: N/A
Study type: Interventional

Patients with Stage IV obstructing colorectal cancer and unresectable liver metastses, with general and local conditions not a risk for coliorectal resection, will be randomized to have either endoscopic stenting or colorectal resection

NCT ID: NCT03280407 Recruiting - Colorectal Cancer Clinical Trials

NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer

NEOLAR
Start date: March 1, 2017
Phase: Phase 2
Study type: Interventional

The main clinical hypothesis is that compared to radio-chemotherapy for low and mid rectal tumors or surgery for high rectal tumors neoadjuvant chemotherapy reduces the rate of distant relapse without increasing the rate of local relapse. The aim of the present study is to compare long term and short term outcomes in rectal cancer patients undergoing standard treatment (radio-chemotherapy/surgery) or experimental neoadjuvant chemotherapy/surgery Furthermore, early surgical and medical complications, the functional outcome, toxicity and quality of life (QoL) may be improved if radiotherapy can be avoided. Exploratory analyses are planned in order to find potential predictive markers for selecting patients to either radio-chemotherapy/surgery or neoadjuvant combination chemotherapy/surgery.

NCT ID: NCT03064828 Recruiting - Colorectal Neoplasm Clinical Trials

Colorectal Polyps Screening With Low-dose CT Colonoscopy

Start date: January 2017
Phase: N/A
Study type: Interventional

This preliminary clinical trial aims to evaluate the performance of the low-dose CT colonoscopy (CTC) with computer aided detection (CAD) on polyps detection compared with optical colonoscopy (OC), and explore the possible clinical routine for integrated use of CT colonoscopy and optical colonoscopy OC in colorectal cancer screening.

NCT ID: NCT02870153 Recruiting - Colorectal Neoplasm Clinical Trials

SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer

Start date: January 2013
Phase: Phase 2
Study type: Interventional

The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (SOX) and Oxaliplatin and Capecitabine (XELOX) in patients with peritoneal metastasis of colorectal cancer.